Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study.
Publication Title
Anticancer research
Document Type
Article
Publication Date
3-1-2019
Keywords
Aged; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Placebos; Prognosis; Survival Analysis
Abstract
BACKGROUND/AIM: The analysis of prognostic factors is important to identify determinants of disease-free survival (DFS) and overall survival (OS) in resected non-small-cell lung cancer (NSCLC).
PATIENTS AND METHODS: We examined baseline characteristics associated with DFS and OS among 757 patients with resected, histologically proven, MAGE-A3-positive Stage IB-IIIA NSCLC assigned to placebo in the MAGRIT study (NCT00480025). We explored characteristics of NSCLC that could predict DFS and OS using Cox regression models.
RESULTS: The multivariate analysis showed that lower nodal stage, the presence of squamous cell carcinoma (SCC), a broader surgical resection in patients with SCC, and being female with non-SCC were significantly associated with longer DFS. Lower nodal stage and smaller tumor size were significantly associated with an improved OS. Compared to Other International, enrollment in East Asia was associated with an improved OS in patients with non-SCC.
CONCLUSION: This is the first prognostic factor analysis in NSCLC performed on data from a large prospective study. These results confirm retrospective studies and add that histopathology subtype is a strong determinant of DFS in resected MAGE-A3-positive NSCLC.
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Pulmonary Medicine
